Design and engineering of artificial biosynthetic pathways-where do we stand and where do we go?

被引:3
|
作者
Sokolova, Nika [1 ]
Peng, Bo [1 ]
Haslinger, Kristina [1 ]
机构
[1] Univ Groningen, Dept Chem & Pharmaceut Biol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands
关键词
biotransformation; engineered microbes; metabolic pathways; sustainability; IN-VITRO; SYNTHETIC BIOLOGY; ESCHERICHIA-COLI;
D O I
10.1002/1873-3468.14745
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The production of commodity and specialty chemicals relies heavily on fossil fuels. The negative impact of this dependency on our environment and climate has spurred a rising demand for more sustainable methods to obtain such chemicals from renewable resources. Herein, biotransformations of these renewable resources facilitated by enzymes or (micro)organisms have gained significant attention, since they can occur under mild conditions and reduce waste. These biotransformations typically leverage natural metabolic processes, which limits the scope and production capacity of such processes. In this mini-review, we provide an overview of advancements made in the past 5 years to expand the repertoire of biotransformations in engineered microorganisms. This ranges from redesign of existing pathways driven by retrobiosynthesis and computational design to directed evolution of enzymes and de novo pathway design to unlock novel routes for the synthesis of desired chemicals. We highlight notable examples of pathway designs for the production of commodity and specialty chemicals, showcasing the potential of these approaches. Lastly, we provide an outlook on future pathway design approaches. Microbial production of commodity and specialty chemicals has the potential to decrease our reliance on fossil fuels and reduce the accompanying environmental effects. The scope of traditional biomanufacturing can be greatly enhanced by constructing new-to-nature pathways toward target chemicals. Here, we outline the principles of artificial pathway design and engineering, highlight notable examples and provide an outlook on its future.image
引用
收藏
页码:2897 / 2907
页数:11
相关论文
共 50 条
  • [1] Artificial Blood and Nanotechnology: Where do We Stand?
    Hakami, Nora Y.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2024, 38 (03) : 1859 - 1873
  • [2] Pegasparaginase: where do we stand?
    Zeidan, Amer
    Wang, Eunice S.
    Wetzler, Meir
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (01) : 111 - 119
  • [3] Environmental Behavior Framework Revisited: Where Do We Stand Ten Years Later and Where Do We Go from Here?
    Pelcher, Jamee A.
    Trendafilova, Sylvia
    McCullough, Brian P.
    SUSTAINABILITY, 2024, 16 (17)
  • [4] Where do we stand on vascular calcification?
    Bostrom, Kristina I.
    VASCULAR PHARMACOLOGY, 2016, 84 : 8 - 14
  • [5] Maximizing neuroprotection: where do we stand?
    Kuffler, Damien P.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2012, 8 : 185 - 194
  • [6] Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
    Luong, Tiffany
    Salabarria, Ann-Charlott
    Roach, Dwayne R.
    CLINICAL THERAPEUTICS, 2020, 42 (09) : 1659 - 1680
  • [7] Rifampicin in periprosthetic joint infections: where do we stand and where are we headed?
    Wouthuyzen-Bakker, Marjan
    Scheper, Henk
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2023, 21 (07) : 695 - 701
  • [8] The Role of Angiogenesis in Haemophilic Arthropathy: Where Do We Stand and Where Are We Going?
    Agapidou, Alexandra
    Stavrakis, Thomas
    Vlachaki, Efthymia
    Anagnostis, Panagiotis
    Vakalopoulou, Sophia
    TURKISH JOURNAL OF HEMATOLOGY, 2016, 33 (02) : 88 - 93
  • [9] Genome Engineering in Cyanobacteria: Where We Are and Where We Need To Go
    Ramey, C. Josh
    Baron-Sola, Angel
    Aucoin, Hanna R.
    Boyle, Nanette R.
    ACS SYNTHETIC BIOLOGY, 2015, 4 (11): : 1186 - 1196
  • [10] Pharmacogenomics and Cardiovascular Disease: Where are We and Where do We go from Here?
    Stein, Ricardo
    Beuren, Thais
    Cela, Luis Ramudo
    Ferrari, Filipe
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2020, 115 (04) : 690 - 700